



Method for drug treatment of noninfectious ocular inflammations

Patent MD 1465 Z

Inventatori: Cușnir Valeriu, Dumbrăveanu Lilia, Groppa Liliana, Cușnir Vitalie, Cușnir Valeriu, Bobescu Nicolae

Background

Non-infectious uveitis is the inflammation of the uvea. This group of diseases with multiple etiology are a continuous challenge for ophthalmologists. Traditional treatment of uveitis could have a lot of adverse effects, that's why the necessity of new medicines is still actual.

Objective of the study

Evaluate the therapeutic efficacy of anti-VEGF (bevacizumab) for non-infectious uveitis compared with traditional method of treatment and assessment of adverse reactions.

Material and Methods

This study include 9 clinical cases with non-infectious uveitis, that were treated repeatedly with traditional methods of treatment according to latest protocols. The result was unsatisfactory due to short remission period (2 weeks - 3 months). Futher, all these patients receive bevacizumab repeatedly. Follow-up period was about 1-5 years.

Results

Inflammatory process was stabilized by administration of bevacizumab in anterior chamber. The effect prolong the remission with at least 4 months and improve central vision. It seems that the duration of remission is significant bigger compared to traditional method of treatment and repeated administration of drug have a cumulative effect.

Conclusion

Bevacizumab (anti-VEGF) prevent non-infectious uveitis recurrence and its complications for 1-5 years.